Results 51 to 60 of about 831 (147)

Hormone Levels and Sexual Functioning After Risk-Reducing Salpingo-Oophorectomy

Sexual Medicine, 2018
Introduction: Women after risk-reducing salpingo-oophorectomy (RRSO) can have impaired sexual functioning, but whether there is an association between hormone levels and sexual functioning is unclear.
Nora Johansen, MD, Astrid H. Liavaag, MD, PhD, Lars Mørkrid, MD, PhD, Trond M. Michelsen, MD, PhD   +3 more
doaj   +1 more source

Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing

Journal of Ovarian Research, 2021
Background Professional society guidelines recommend risk-reducing salpingo-oophorectomy (RRSO) for women with pathogenic variants (PVs) in ovarian cancer-risk genes. Personalization of that intervention is based on gene-specific phenotypes; however, the
Shelly Cummings, Susana San Roman, Jennifer Saam, Ryan Bernhisel, Krystal Brown, Johnathan M. Lancaster, Lydia Usha   +6 more
doaj   +1 more source

Ujemne RRSO sposobem na pozyskanie pożyczkobiorców

Studia i Prace Kolegium Zarządzania i Finansów
W sytuacji wyjątkowo niskich stóp procentowych produkty kredytowe z rzeczywistą roczną stopą oprocentowania (RRSO) równą 0% stały się popularne także w Polsce. Autorzy wykazują, że zero nie musi wcale stanowić dolnej granicy wartości tego miernika i przy niewielkim koszcie dla instytucji kredytującej możliwe jest stworzenie produktów kredytowych, w ...
Magdalena Redo, Piotr Prewysz-Kwinto
openaire   +1 more source

Barriers and motivators for BRCA genetic testing in Japan

Journal of Genetic Counseling, Volume 35, Issue 1, February 2026.
Abstract In Japan, insurance coverage for BRCA genetic testing was expanded in 2020. The reasons individuals undergo or decline testing remain unclear; however, cost has been identified as a key factor. Herein, we investigated barriers and motivators for undergoing testing.
Katsuyuki Konnai, Hiroyuki Fujiwara, Eri Haneda, Ann Sato, Haruya Saji, Hiroto Narimatsu   +5 more
wiley   +1 more source

The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients – Slovenian population based study

Radiology and Oncology, 2020
We assessed the prevalence, localization, type and outcome of occult cancer at risk-reducing salpingo-oophorectomy or salpingectomy (RRSO) in asymptomatic carriers of pathogenic or likely pathogenic BRCA1/2 variants and high-risk BRCA1/2 negative women.
Gornjec Andreja, Merlo Sebastijan, Novakovic Srdjan, Stegel Vida, Gazic Barbara, Perhavec Andraz, Blatnik Ana, Krajc Mateja   +7 more
doaj   +1 more source

Breast Cancer: Molecular Pathogenesis, Targeted Therapy, Screening, and Prevention

MedComm, Volume 7, Issue 1, January 2026.
The review manuscript examines the molecular pathogenesis, screening, prevention advances, and evolving targeted therapies in breast cancer. It highlights the integration of AI and multiomics for precision prevention and personalized treatment, pointing toward future directions in equitable cancer care.
Huijun Lei, Jinzhen Fu, Wei Gu, Hongjin Qiao, Huixue Guo, Zijian Chen, San Ming Wang, Tianhui Chen   +7 more
wiley   +1 more source

Nominalny Roczny Koszt Kredytu (NRKK) kontra myląco nazwana i niepoprawnie obliczana Rzeczywista Roczna Stopa Oprocentowania (RRSO)

Studia i Prace Kolegium Zarządzania i Finansów, 2023
Artykuł dotyczy rzeczywistej rocznej stopy oprocentowania (RRSO) – wskaźnika, którego wyliczanie i publikację przez instytucje kredytowe narzuciły dyrektywy unijne oraz ustawa o kredycie konsumenckim.Celem badań jest wykazanie, że przyjęta w języku polskim nazwa tej miary jest nieprawidłowa oraz wyjaśnienie, że nie informuje ona o rzeczywistym koszcie ...
Magdalena Redo, Piotr Prewysz-Kwinto
openaire   +1 more source

Serous Tubal Intraepithelial Carcinoma: A Concise Review for the Practicing Pathologist and Clinician

Diagnostics, 2020
Ovarian cancer is the deadliest gynecologic malignancy, accounting for more than 14,000 deaths each year. With no established way to prevent or screen for it, the vast majority of cases are diagnosed as International Federation of Gynecology and ...
S. Emily Bachert, Anthony McDowell, Dava Piecoro, Lauren Baldwin Branch   +3 more
doaj   +1 more source

An explainable machine learning ensemble model to predict the risk of ovarian cancer in BRCA-mutated patients undergoing risk-reducing salpingo-oophorectomy

Frontiers in Oncology, 2023
IntroductionIt has been estimated that 19,880 new cases of ovarian cancer had been diagnosed in 2022. Most epithelial ovarian cancer are sporadic, while in 15%–25% of cases, there is evidence of a familial or inherited component. Approximately 20%–25% of
Maria Colomba Comes, Francesca Arezzo, Francesca Arezzo, Gennaro Cormio, Gennaro Cormio, Samantha Bove, Angela Calabrese, Annarita Fanizzi, Anila Kardhashi, Daniele La Forgia, Francesco Legge, Isabella Romagno, Vera Loizzi, Vera Loizzi, Raffaella Massafra   +14 more
doaj   +1 more source

The TESTBREAST journey: Revisiting the importance of early detection by frequent screening of women at high risk of breast cancer

International Journal of Cancer, Volume 157, Issue 4, Page 741-751, 15 August 2025.
What's new? Women who are at high risk of breast cancer (BC), either because of a BRCA1/2 mutation or family history, require more aggressive screening. Here, the authors report on the clinical characteristics of the high‐risk women who developed BC during the TESTBREAST study. Of the 1108 participants, 124 (16.5%) developed breast cancer. Their median
Layla Andour, Sophie C. Hagenaars, Kiki Vangangelt, Janneke Aalberts, Valerie Rebattu, Dorien M. A. Berends van der Meer, Elma Meershoek‐Klein Kranenbarg, Katja N. Gaarenstroom, Christi J. van Asperen, Rob A. E. M. Tollenaar, Wilma E. Mesker, on behalf of the TESTBREAST study team, J. Aalberts, T. M. A. Berends‐van der Meer, S. C. Hagenaars, L. Andour, W.E. Mesker, R. A. E. M Tollenaar, W. M. Meershoek‐Klein Kranenbarg, K. N. Gaarenstroom, C. M. R. Haekens, K. B. M. I. Keymeulen, J. Remmelzwaal, M. Piek‐den Hartog, E. J. T. Rutgers, C. Drukker, C. Lemstra, A. Prozee, J. de Vries, A. Stam, C. Bandel, I. Meijer, A. E. Dassen, S. Makineli, E. E. van Oers‐Hazelzet, A. J. Witkamp, K. E. Schenk, W. van der Eijk, M. B. E. Menke‐Pluijmers, J. de Droog‐Laane, B. A. Kortmann   +40 more
wiley   +1 more source